Accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology.

Our Science

We are identifying and utilizing new ways to address cancer at its core. Combining our expertise in molecular cancer biology, epigenetics, cancer stem cell biology, with preclinical and clinical drug development, we are creating novel therapeutics to unlock new pathways to treat advanced cancers.

follow the science

Our Targets

Our targets represent previously unexplored mechanisms of cancer regulation.

KDM4 is a family of histone lysine demethylases that regulate epigenetic processes which can lead to altered gene function and malignant cellular transformation.

Learn More

LEFTY1 is a member of the transforming growth factor beta (TGF-β) superfamily that promotes long-term growth and self-renewal of cancer stem cells.

Learn More

Innovators in Our Field

Tachyon operates with a dedicated internal core development team and a broad virtual external network of expertise to achieve one goal – advance our program with speed and innovation, without compromising the quality or integrity of our science.

Meet the tachyon team

Accelerating Science for Breakthrough Therapies